[go: up one dir, main page]

NO20081087L - Fremgangsmater for fremstilling av sterilisert pankreatinpulver - Google Patents

Fremgangsmater for fremstilling av sterilisert pankreatinpulver

Info

Publication number
NO20081087L
NO20081087L NO20081087A NO20081087A NO20081087L NO 20081087 L NO20081087 L NO 20081087L NO 20081087 A NO20081087 A NO 20081087A NO 20081087 A NO20081087 A NO 20081087A NO 20081087 L NO20081087 L NO 20081087L
Authority
NO
Norway
Prior art keywords
methods
pancreatin
pancreatin powder
preparing sterilized
sterilized
Prior art date
Application number
NO20081087A
Other languages
English (en)
Other versions
NO340996B1 (no
Inventor
Martin Frink
Claus-Juergen Koelln
Heinz Blume
Michael Rust
Original Assignee
Abbott Lab Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35457614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20081087(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab Gmbh filed Critical Abbott Lab Gmbh
Publication of NO20081087L publication Critical patent/NO20081087L/no
Publication of NO340996B1 publication Critical patent/NO340996B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/94—Pancreatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A61L2/04—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Nutrition Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Det er beskrevet fremgangsmåte for fremstilling av pankreatin hvor konsentrasjonen av én eller flere biologiske forurensninger er redusert, slik som virus og/eller bakterier, hvor fremgangsmåten omfatter oppvarming av pankreatinet ved en temperatur på minst 85 °C ved et totalt innhold av oppløsningsmidler som er lavere enn 9 vekt%. Videre er det beskrevet et pankreatin som lar seg erholde ved hjelp av en slik fremgangsmåte.
NO20081087A 2005-07-29 2008-02-29 Fremgangsmåter for fremstilling av pankreatin som er redusert i virus-forurensninger NO340996B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70381305P 2005-07-29 2005-07-29
EP05016533 2005-07-29
PCT/EP2006/064717 WO2007014896A1 (en) 2005-07-29 2006-07-27 Processes for the manufacture of sterilized pancreatin powder

Publications (2)

Publication Number Publication Date
NO20081087L true NO20081087L (no) 2008-04-28
NO340996B1 NO340996B1 (no) 2017-07-31

Family

ID=35457614

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20081087A NO340996B1 (no) 2005-07-29 2008-02-29 Fremgangsmåter for fremstilling av pankreatin som er redusert i virus-forurensninger
NO20171131A NO342419B1 (no) 2005-07-29 2017-07-07 Pankreatin som er redusert i virus-forurensninger, og farmasøytisk sammensetning derav

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20171131A NO342419B1 (no) 2005-07-29 2017-07-07 Pankreatin som er redusert i virus-forurensninger, og farmasøytisk sammensetning derav

Country Status (17)

Country Link
US (3) US20070148151A1 (no)
EP (2) EP2278002B1 (no)
JP (1) JP5140586B2 (no)
KR (1) KR101555058B1 (no)
CN (1) CN101233229B (no)
AU (1) AU2006274835B2 (no)
BR (1) BRPI0614914A2 (no)
CA (1) CA2616943C (no)
ES (2) ES2635308T3 (no)
HU (2) HUE034739T2 (no)
IL (1) IL189103A (no)
MX (1) MX2008000850A (no)
NO (2) NO340996B1 (no)
PL (2) PL1913138T3 (no)
RU (1) RU2413532C2 (no)
UA (1) UA93384C2 (no)
WO (1) WO2007014896A1 (no)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US8100844B2 (en) * 2002-04-25 2012-01-24 Ultraflex Systems, Inc. Ambulating ankle and knee joints with bidirectional dampening and assistance using elastomeric restraint
RU2381813C2 (ru) 2004-03-22 2010-02-20 Зольвай Фармасьютиклз Гмбх Пероральные фармацевтические композиции на основе продуктов, содержащих липазы, прежде всего панкреатин, и пав
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
PL1913138T3 (pl) 2005-07-29 2017-07-31 Abbott Laboratories Gmbh Sposoby wytwarzania pankreatyny w proszku o niskiej zawartości wirusa
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
TWI421090B (zh) 2007-02-20 2014-01-01 Aptalis Pharma Ltd 穩定之消化酵素組合物
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
CA2701340C (en) 2007-11-15 2016-06-28 Solvay Pharmaceuticals Gmbh Novel process for separating and determining the viral load in a pancreatin sample
US10087493B2 (en) * 2008-03-07 2018-10-02 Aptalis Pharma Canada Ulc Method for detecting infectious parvovirus in pharmaceutical preparations
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US20090324730A1 (en) * 2008-06-26 2009-12-31 Fallon Joan M Methods and compositions for the treatment of symptoms of complex regional pain syndrome
US11016104B2 (en) * 2008-07-01 2021-05-25 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) * 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
EP2165717A1 (de) 2008-08-27 2010-03-24 Nordmark Arzneimittel GmbH & Co.KG Verfahren zur Verringerung der viralen und mikrobiellen Belastung feststoffhaltiger biologischer Extrakte
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
DE202008014562U1 (de) 2008-11-03 2009-02-26 Nordmark Arzneimittel Gmbh & Co. Kg Pankreatin
ATE541591T1 (de) * 2008-11-03 2012-02-15 Nordmark Arzneimittel Gmbh & Co Kg Verfahren zur verringerung der viralen und mikrobiellen belastung von pankreatin
CA2747703C (en) 2009-01-06 2021-06-15 Curemark Llc Compositions and methods for the treatment or the prevention of infections by e. coli
BRPI1007378A2 (pt) 2009-01-06 2020-08-18 Curemark Llc composições e métodos para o tratamento ou prevenção de infecções por staphylococcus aureus e para a erradicação ou redução de staphylococcus aureus sobre superfícies.
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US8784884B2 (en) 2009-09-17 2014-07-22 Stephen Perrett Pancreatic enzyme compositions and methods for treating pancreatitis and pancreatic insufficiency
WO2011050135A1 (en) 2009-10-21 2011-04-28 Curemark Llc Methods and compositions for the prevention and treatment of influenza
EP2547765A4 (en) * 2010-03-19 2013-09-04 Aptalis Pharma Canada Inc BETA-PROPIOLACTONE FOR INACTIVATING VIRUSES IN PANCREATIC PHARMACEUTICAL ENZYMATIC PREPARATIONS
PT2621476E (pt) 2010-10-01 2014-10-16 Aptalis Pharma Ltd Formulações de pancrelipase de baixa potência com revestimento entérico
EP2701733B1 (en) 2011-04-21 2019-04-03 Curemark, LLC Compounds for the treatment of neuropsychiatric disorders
DK2741766T3 (en) 2011-08-08 2016-01-11 Aptalis Pharma Ltd Process for dissolving solid compositions containing digestive enzymes
JP5814094B2 (ja) * 2011-11-30 2015-11-17 ふたみ青果株式会社 遠赤外線ヒーターによる凍結乾燥方法とその装置
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US10184121B2 (en) 2013-06-28 2019-01-22 Allergan Pharmaceuticals International Limited Methods for removing viral contaminants from pancreatic extracts
RU2679832C2 (ru) 2013-08-09 2019-02-13 Аллерган Фармасьютикалз Интернэйшнл Лимитед Композиция пищеварительных ферментов, подходящая для энтерального введения
EP3613429A1 (en) 2013-11-05 2020-02-26 Allergan Pharmaceuticals International Limited High potency pancreatin pharmaceutical compositions
RU2712142C2 (ru) 2014-11-05 2020-01-24 Эбботт Лабораторис Гмбх Способы получения композиций с улучшенным профилем безопасности, содержащих панкреатин, и композиции, пригодные для фармацевтического применения
EP3298139B1 (en) * 2015-05-19 2021-09-15 Scientific Protein Laboratories LLC Method for reducing or inactivating viral and microbial content in the processes for the manufacture of pancreatin
DE102015119006A1 (de) 2015-11-05 2017-05-11 Nordmark Arzneimittel Gmbh & Co. Kg Verfahren zur Reduzierung der Belastung von Pankreatin mit Mikroorganismen
US11278603B2 (en) 2016-03-28 2022-03-22 Abbvie Inc. Enzyme compositions with reduced viral and microbial contamination
CN109475610A (zh) 2016-03-28 2019-03-15 雅培制药股份有限公司 病毒和微生物污染减少的酶组合物
KR101813920B1 (ko) * 2016-07-06 2018-01-04 넨시스(주) 판크레아틴의 살균방법 및 이를 이용한 판크레아틴 제조방법
US12226464B2 (en) 2017-04-10 2025-02-18 Curemark, Llc Compositions for treating addiction
EA202090851A1 (ru) * 2017-09-27 2020-08-07 Эбботт Лэбораториз Гмбх Ферментные композиции со сниженным уровнем вирусного и микробного загрязнения
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Family Cites Families (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2189948A (en) 1938-10-31 1940-02-13 Griffith Laboratories Sterilization of pancreatin
US2503313A (en) 1947-04-14 1950-04-11 Levin Ezra Production of dried, defatted enzymatic material
US3324002A (en) * 1962-09-17 1967-06-06 Armour Pharma Anti-inflammatory preparations containing proteolytic enzymes and adrenal glucocorticoids
US3803305A (en) * 1962-12-28 1974-04-09 Rolland A Lab Process for obtaining extracts from pancreas
US3956483A (en) * 1968-10-24 1976-05-11 Wilson Pharmaceutical & Chemical Corporation Preparing pancreatin
DE2035739A1 (en) 1970-07-18 1972-01-27 Röhm FmbH, 6100 Darmstadt Oral enzyme prepsn - consisting of granulate with gastric juices-resistant coating in tablet or capsule form
US3991180A (en) * 1972-03-06 1976-11-09 Rohm And Haas Company Stabilization of internally administered pancreatic lipase
FR2183546B1 (no) * 1972-05-10 1975-06-20 Servier Lab
JPS4936886A (no) 1972-08-15 1974-04-05
JPS5543723B2 (no) 1972-08-24 1980-11-07
DE2410241A1 (de) 1974-03-04 1975-09-18 Christian Brunnengraeber Chem Granulataehnliche darreichungsform fuer arzneimittel
DE2512746C3 (de) * 1975-03-22 1980-04-24 Kali-Chemie Pharma Gmbh, 3000 Hannover Verfahren zur Herstellung von keimarmem, faserfreiem Pankreatin
US3986927A (en) * 1975-04-28 1976-10-19 Armour Pharmaceutical Company Process for the purification and sterilization of acidophilic biologicals by extreme acidification at cold temperatures
GB1509866A (en) * 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
GB1590432A (en) * 1976-07-07 1981-06-03 Novo Industri As Process for the production of an enzyme granulate and the enzyme granuate thus produced
GB1603640A (en) 1977-07-20 1981-11-25 Gist Brocades Nv Enzyme particles
JPS5535031A (en) 1978-09-04 1980-03-11 Shin Etsu Chem Co Ltd Enteric coating composition
US4259440A (en) 1979-05-21 1981-03-31 Miles Laboratories, Inc. Hydrolysis and assay of triglycerides
DE2923279C2 (de) 1979-06-08 1987-07-09 Kali-Chemie Pharma Gmbh, 3000 Hannover Verfahren zur Herstellung von Pankreatin-Pellets und diese enthaltende Arzneimittel
JPS5855125B2 (ja) 1980-03-10 1983-12-08 信越化学工業株式会社 固形薬剤用腸溶性コ−テイング剤組成物
JPS57171428A (en) * 1981-04-13 1982-10-22 Sankyo Co Ltd Preparation of coated solid preparation
US4495278A (en) 1981-04-27 1985-01-22 Baxter Travenol Laboratories, Inc. Process for making novel blood clotting enzyme compositions
US4456590B2 (en) 1981-11-02 1989-05-30 Heat treatment of lyphilized blood clotting factor viii concentrate
JPS58148814A (ja) 1982-03-01 1983-09-05 Fujimoto Seiyaku Kk 消化酵素軟カプセル剤
JPS58179492A (ja) 1982-04-12 1983-10-20 Dainichi Seika Kogyo Kk 洗剤用酵素粒剤およびその製造方法
EP0115023B1 (de) * 1982-12-30 1988-07-27 Nordmark Arzneimittel GmbH Verfahren zur Gewinnung von Pankreatin
US4447412A (en) * 1983-02-01 1984-05-08 Bilton Gerald L Enzyme-containing digestive aid compostions
JPS59169491A (ja) 1983-03-15 1984-09-25 Duskin Franchise Co Ltd 酵素の安定化法
IE55711B1 (en) 1983-10-24 1990-12-19 Bausch & Lomb Improved method for enzymatic cleaning and disinfecting contact lenses
US4490361A (en) * 1983-12-02 1984-12-25 Alpha Therapeutic Corporation Virus inactivating heat treatment of plasma fractions
JPS61162185A (ja) 1985-01-09 1986-07-22 Nagase Seikagaku Kogyo Kk 顆粒状酵素製剤の製造方法
US4689297A (en) * 1985-03-05 1987-08-25 Miles Laboratories, Inc. Dust free particulate enzyme formulation
US4707287A (en) 1985-06-28 1987-11-17 The Procter & Gamble Company Dry bleach stable enzyme composition
JPH0622461B2 (ja) 1985-07-31 1994-03-30 キユーピー株式会社 水中油型乳化食品の製造方法
US4775536A (en) * 1986-02-24 1988-10-04 Bristol-Myers Company Enteric coated tablet and process for making
US5766912A (en) * 1986-03-17 1998-06-16 Novo Nordisk A/S Humicola lipase produced in aspergillus
DK122686D0 (da) 1986-03-17 1986-03-17 Novo Industri As Fremstilling af proteiner
US5536661A (en) * 1987-03-10 1996-07-16 Novo Nordisk A/S Process for the production of protein products in aspergillus
US5874558A (en) * 1986-03-17 1999-02-23 Novo Nordisk Nucleic acid encoding a recombinant humicola sp. lipase
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
EP0270608B1 (en) 1986-05-21 1990-08-22 Novo Nordisk A/S Coated detergent enzymes
DE3642853A1 (de) 1986-12-16 1988-06-23 Ulrich Von Dr Ing Pidoll Arzneimittel
DK435687D0 (da) 1987-08-21 1987-08-21 Novo Industri As Enzymholdigt granulat og fremgangsmaade til fremstilling deraf
DK435587D0 (da) 1987-08-21 1987-08-21 Novo Industri As Fremgangsmaade til fremstilling af et enzymholdigt granulat
ES2076939T3 (es) 1987-08-28 1995-11-16 Novo Nordisk As Lipasa recombinante de humicola y procedimiento para la produccion de lipasas recombinantes de humicola.
US5068110A (en) * 1987-09-29 1991-11-26 Warner-Lambert Company Stabilization of enteric coated dosage form
IL88961A (en) * 1988-01-29 1992-07-15 Basf Ag Stable mixtures containing oxidation-sensitive compounds
JP2624860B2 (ja) 1988-03-14 1997-06-25 ノボ‐ノルディスク アクティーゼルスカブ 安定化粒状組成物
DK78089D0 (da) 1989-02-20 1989-02-20 Novo Industri As Detergentholdigt granulat og fremgangsmaade til fremstilling deraf
DK78189D0 (da) 1989-02-20 1989-02-20 Novo Industri As Enzymholdigt granulat og fremgangsmaade til fremstilling deraf
US5219572A (en) * 1989-03-17 1993-06-15 Pitman-Moore, Inc. Controlled release delivery device for macromolecular proteins
ATE138575T1 (de) * 1989-06-15 1996-06-15 Rorer Int Overseas Verfahren zur inaktivierung von viren in mit viren verunreinigten pharmazeutischen zusammensetzungen
GB8915658D0 (en) 1989-07-07 1989-08-23 Unilever Plc Enzymes,their production and use
US5658871A (en) * 1989-07-07 1997-08-19 Lever Brothers Company, Division Of Conopco, Inc. Microbial lipase muteins and detergent compositions comprising same
AU6719090A (en) 1989-10-31 1991-05-31 Genencor International, Inc. Dust-free coated enzyme formulation
KR100229754B1 (ko) 1989-11-24 1999-11-15 샬러 한스, 하우스 한스 루돌프 판크레아틴구형입자, 이의 제조방법 및 이를 함유하는 약제학적 조성물
US6187572B1 (en) * 1990-04-16 2001-02-13 Baxter International Inc. Method of inactivation of viral and bacterial blood contaminants
ATE232737T1 (de) 1990-04-16 2003-03-15 Baxter Int Methode zur unschädlichmachung viraler und bakterieller blutverunreinigungen
JP3110437B2 (ja) 1990-05-17 2000-11-20 財団法人化学及血清療法研究所 流行性非ａ非ｂ型肝炎ウイルス抗原ペプチドおよびこれをコードする核酸断片
DK173590D0 (da) 1990-06-06 1990-07-19 Novo Nordisk As Rekombinante terapeutiske lipaser
US5801022A (en) * 1990-08-03 1998-09-01 Vertex Pharmaceuticals, Incorporated Method of producing a product with crosslinked crystals of thermolysin
CA2087730C (en) 1990-08-03 1999-07-20 Manuel A. Navia Use of crosslinked crystals as a novel form of enzyme immobilization
US5618710A (en) * 1990-08-03 1997-04-08 Vertex Pharmaceuticals, Inc. Crosslinked enzyme crystals
US5869438A (en) * 1990-09-13 1999-02-09 Novo Nordisk A/S Lipase variants
JP3055799B2 (ja) 1990-11-21 2000-06-26 塩野義製薬株式会社 パンクレアチン含有組成物
US5254283A (en) 1991-01-17 1993-10-19 Genencor International, Inc. Isophthalic polymer coated particles
NZ241359A (en) * 1991-01-24 1994-08-26 Martek Corp Supplementation of infant formula by the addition of at least two different polyunsaturated fatty acids obtained from at least two different microbial sources; compositions comprising such oils
DK13491D0 (da) 1991-01-25 1991-01-25 Novo Nordisk As Anvendelse af et enzymholdigt granulat og fremgangsmaade til fremstilling af et forderstof i tabletform
DE4203315A1 (de) 1991-02-14 1992-08-20 Kali Chemie Pharma Gmbh Verfahren zur gewinnung von pankreatin
CA2110497C (en) * 1991-07-01 2005-04-19 Reinhard Braatz Use of bacterial lipases for producing drugs for maldigestion therapy
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
US5879920A (en) * 1991-10-07 1999-03-09 Genencor International, Inc. Coated enzyme-containing granule
DK0610321T3 (da) 1991-10-07 2002-04-08 Genencor Int Granule indeholdende coatet enzym
US5324649A (en) * 1991-10-07 1994-06-28 Genencor International, Inc. Enzyme-containing granules coated with hydrolyzed polyvinyl alcohol or copolymer thereof
WO1993007260A1 (en) 1991-10-10 1993-04-15 Genencor International, Inc. Process for dust-free enzyme manufacture
DE4200002A1 (de) 1992-01-02 1993-07-08 Rudolf V Dipl Chem Dr Noronha Reinigungstablette fuer die zahnprothesen
US5686238A (en) 1992-02-10 1997-11-11 Baxter International Inc. Method and device for testing blood units for viral contamination
EP0713397B1 (en) 1992-03-24 2002-12-11 United Cancer Research Institute Vaccine containing live virus
US5302400A (en) * 1992-06-22 1994-04-12 Digestive Care Inc. Preparation of gastric acid-resistant microspheres containing digestive enzymes and buffered-bile acids
US5260074A (en) * 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
DE4227385A1 (de) * 1992-08-19 1994-02-24 Kali Chemie Pharma Gmbh Pankreatinmikropellets
JPH08502490A (ja) 1992-10-16 1996-03-19 スミスクライン・ビーチャム・コーポレイション 組成物
JP3264027B2 (ja) * 1993-02-24 2002-03-11 ソニー株式会社 放電セル及びその製造方法
DK39693D0 (da) 1993-04-02 1993-04-02 Novo Nordisk As Enzym
DE4322229A1 (de) 1993-07-05 1995-01-12 Cognis Bio Umwelt Umhüllte Enzymzubereitung für Wasch- und Reinigungsmittel
EP0719133A1 (en) 1993-09-15 1996-07-03 Unilever Plc Skin care method and composition
US6054136A (en) * 1993-09-30 2000-04-25 Gattefosse S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
US6312704B1 (en) * 1993-09-30 2001-11-06 Gattefosse, S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
FR2710535B1 (fr) 1993-09-30 1995-11-24 Gattefosse Ets Sa Composition à usage pharmaceutique ou cosmétique apte à former une microémulsion.
DE4344215A1 (de) 1993-12-23 1995-06-29 Cognis Bio Umwelt Silberkorrosionsschutzmittelhaltige Enzymzubereitung
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
JP2917799B2 (ja) * 1994-03-11 1999-07-12 田辺製薬株式会社 消化管内適所放出型製剤
DE4422198C2 (de) 1994-06-24 1997-08-28 Audi Ag Verfahren zum Steuern der elektrischen Beheizung eines Katalysators
JP3355593B2 (ja) * 1994-08-19 2002-12-09 信越化学工業株式会社 固形腸溶製剤の製造方法
DE69519944T2 (de) 1994-11-18 2001-06-13 Genencor International, Inc. Umhüllte enzymgranulate
JPH08143457A (ja) 1994-11-21 1996-06-04 Microbial Chem Res Found 酵素阻害剤および高脂血症抑制剤
WO1996038527A1 (en) 1995-05-29 1996-12-05 Kao Corporation Enzyme-containing granulated substance and preparation process thereof
EP0828509B1 (en) 1995-05-31 2005-01-26 Medzyme N.V. Composition to improve digestibility and utilisation of nutrients
JPH09125096A (ja) 1995-10-30 1997-05-13 Koei Sangyo:Kk 液状天然油脂洗剤
AU1200997A (en) 1995-12-22 1997-07-17 Helix Biotechnology Ltd Thermostable proteolytic enzyme from thermoactinomyces thalpophilus thm1
ID18663A (id) * 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
CN1135265C (zh) 1996-04-12 2004-01-21 诺沃奇梅兹有限公司 含酶颗粒及其生产方法
WO1997041215A1 (en) * 1996-04-29 1997-11-06 Novo Nordisk A/S Non-aqueous, liquid, enzyme-containing compositions
US6632648B1 (en) 1996-05-14 2003-10-14 Elan Drug Delivery Limited Methods of terminal sterilization of fibrinogen
US5750104A (en) * 1996-05-29 1998-05-12 Digestive Care Inc. High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith
GB9613858D0 (en) 1996-07-02 1996-09-04 Cortecs Ltd Hydrophobic preparations
DE19724845A1 (de) 1996-08-28 1998-03-05 Solvay Pharm Gmbh Verwendung von komplexen Lipiden als stabilisierende Zusätze zu pharmazeutischen Zubereitungen von Verdauungsenzymgemischen
GB9624927D0 (en) * 1996-11-29 1997-01-15 Oxford Glycosciences Uk Ltd Gels and their use
CA2198317C (en) 1997-02-24 2003-01-07 Mouhsine El Abboudi Method for preparing pancreatin which contains low amounts of residual organic solvent and product thereof
US6140475A (en) * 1997-04-11 2000-10-31 Altus Biologics Inc. Controlled dissolution crosslinked protein crystals
AUPO693397A0 (en) 1997-05-22 1997-06-12 Betatene Limited Carotenoid formulation
NZ330940A (en) 1997-07-24 2000-02-28 F Production of consensus phytases from fungal origin using computer programmes
ES2137862B1 (es) 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
JP3611456B2 (ja) * 1997-09-30 2005-01-19 日研化学株式会社 テオフィリン徐放性錠剤
KR100387245B1 (ko) 1997-10-17 2003-08-19 일양약품주식회사 유산균의안정화를위한미세장용성코팅과립
PL344534A1 (en) 1997-11-28 2001-11-05 Innogenetics Nv Synthetic peptides containing citrulline recognized by rheumatoid arthritis sera as tools for diagnosis and treatment
KR19990072826A (ko) 1998-02-26 1999-09-27 우재영 판크레아틴장용코팅과립의제조방법
FR2775597B1 (fr) 1998-03-04 2001-04-20 Gattefosse Ets Sa Pellet administrable par voie orale apte a ameliorer la biodisponibilite de la substance active, procede de fabrication
US20030021844A1 (en) 1998-03-04 2003-01-30 Philippe Barthelemy Immediate-release oral pellet comprising polyglycolysed glycerides, and manufacturing process
BR9908692A (pt) * 1998-03-09 2001-12-04 Ista Pharmaceuticals Inc Uso de agentes de enrijecimento corneal emortocerotologia enzimática
US7122207B2 (en) * 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
UA69413C2 (uk) 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
DE29824797U1 (de) 1998-05-22 2002-08-22 Bristol-Myers Squibb Co., Princeton, N.J. Magensaftresistent überzogene Arzneimittel
CN1192087C (zh) 1998-06-30 2005-03-09 诺沃奇梅兹有限公司 一种新的改进的含酶颗粒
US6268329B1 (en) * 1998-06-30 2001-07-31 Nouozymes A/S Enzyme containing granule
DE19848849A1 (de) 1998-10-22 2000-04-27 Knoll Ag Verfahren zur Herstellung von festen, sphärischen Formen, enthaltend eine biologisch aktive Substanz
DE19856415C2 (de) 1998-12-08 2001-06-07 Thomas Fenner Verfahren zur Reinigung bzw. Isolierung viraler Nukleinsäuren
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2000054799A2 (de) 1999-03-17 2000-09-21 Solvay Pharmaceuticals Gmbh Arzneimittel zur behandlung von diabetes
WO2000073429A1 (en) 1999-05-27 2000-12-07 Amano Enzyme Inc. Enzyme liquor and process for producing the same, enzyme preparation, protease preparations and protease-producing bacterium
EP1224273B1 (en) 1999-10-01 2007-10-17 Novozymes A/S Enzyme granulate
DK1138333T3 (da) 1999-10-12 2004-05-24 Daiichi Suntory Pharma Co Ltd Medicinske præparater til oral anvendelse
CZ299726B6 (cs) * 1999-11-01 2008-11-05 Lécivo pro lécení zácpy a syndromu dráždivého tracníku
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AU2755201A (en) * 1999-12-30 2001-07-16 Kemin Industries, Inc. Method for improving the activity of enzymes
PL200047B1 (pl) 2000-02-08 2008-11-28 Dsm Ip Assets Bv Zastosowanie trwałych w kwasie proteaz w karmie zwierzęcej, dodatek do karmy i karma zwierzęca
US20010046493A1 (en) 2000-02-24 2001-11-29 Alex Margolin Lipase-containing composition and methods of use thereof
KR20010100194A (ko) 2000-03-13 2001-11-14 박호군 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US20020146451A1 (en) * 2000-07-15 2002-10-10 Sharma Virender K. Method for the administration of acid-labile drugs
CN1336434A (zh) * 2000-08-01 2002-02-20 上海惠海生化制品厂 胰激肽原酶的制备及其亲和层析纯化方法
CN1452657A (zh) 2000-09-08 2003-10-29 诺和酶股份有限公司 润滑颗粒
WO2002028369A1 (en) 2000-10-02 2002-04-11 Novozymes A/S Coated particles containing an active substance
RU2299074C2 (ru) * 2000-11-02 2007-05-20 Цилиан Аг Применение полученных из инфузорий ферментов в качестве способствующих пищеварению лекарственных средств
IT1319655B1 (it) * 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
AR032392A1 (es) 2001-01-19 2003-11-05 Solvay Pharm Gmbh Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.
US6692771B2 (en) * 2001-02-23 2004-02-17 Cima Labs Inc. Emulsions as solid dosage forms for oral administration
US6676933B2 (en) * 2001-05-23 2004-01-13 Osmotica Corp. Pharmaceutical composition containing mosapride and pancreatin
EP1279402B1 (en) 2001-07-26 2006-11-29 Ethypharm Coated granules of allylamine-or benzylamine-anti-mycotics, process for preparation thereof and orodispersible tablets containing said coated granules
FR2827770B1 (fr) * 2001-07-27 2005-08-19 Gattefosse Ets Sa Composition pharmaceutique a usage oral comprenant un principe actif susceptible de subir un important effet de premier passage intestinal
US6749851B2 (en) * 2001-08-31 2004-06-15 Clearant, Inc. Methods for sterilizing preparations of digestive enzymes
US6783968B2 (en) * 2001-09-24 2004-08-31 Clearant, Inc. Methods for sterilizing preparations of glycosidases
EA008072B1 (ru) 2001-12-03 2007-02-27 Новацея, Инк. Фармацевтические составы, содержащие соединения активного витамина d
AU2002351749A1 (en) 2001-12-21 2003-07-15 Novozymes A/S Salt coatings
US20040009953A1 (en) * 2002-01-10 2004-01-15 Comper Wayne D. Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
JP2005520546A (ja) 2002-03-27 2005-07-14 ノボザイムス アクティーゼルスカブ フィラメントコーティングを有する粒体
RU2207847C1 (ru) * 2002-04-15 2003-07-10 Открытое акционерное общество "Биосинтез" Фармацевтическая композиция, применяемая при заболеваниях поджелудочной железы
GB0216002D0 (en) * 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
US20040161423A1 (en) * 2002-07-18 2004-08-19 Sanjeev Kumar (Mendiratta) Polymer modified anti-angiogenic serpins
CN1756767A (zh) 2003-02-06 2006-04-05 诺和酶股份有限公司 在丝状真菌中表达人重链抗体
US20040213847A1 (en) * 2003-04-23 2004-10-28 Matharu Amol Singh Delayed release pharmaceutical compositions containing proton pump inhibitors
EP1651962B1 (en) 2003-07-29 2013-09-11 Abbott Laboratories GmbH Analytical method for pancreatin and comparable compositions
WO2005070962A1 (en) 2004-01-21 2005-08-04 Novozymes A/S Production of a monoclonal antibody in a heterokaryon fungus or in a fungal host cell
RU2381813C2 (ru) 2004-03-22 2010-02-20 Зольвай Фармасьютиклз Гмбх Пероральные фармацевтические композиции на основе продуктов, содержащих липазы, прежде всего панкреатин, и пав
JP4936885B2 (ja) 2004-04-23 2012-05-23 出光興産株式会社 マグネシウム化合物、オレフィン重合用触媒及びオレフィン重合体の製造方法
ITMI20040891A1 (it) 2004-05-04 2004-08-04 Ibsa Inst Biochimique Sa Nuovo metodo per la partizione ed inattivazione di contaminanti virali e prionici
PT2198880T (pt) 2004-10-14 2017-01-04 Lilly Co Eli Composições contendo lipase, protease e amilase para o tratamento de insuficiência pancreática
US20090047266A1 (en) 2005-06-24 2009-02-19 Novozymes A/S Lipases for Pharmaceutical Use
PL1913138T3 (pl) 2005-07-29 2017-07-31 Abbott Laboratories Gmbh Sposoby wytwarzania pankreatyny w proszku o niskiej zawartości wirusa
US7951384B2 (en) 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US9198871B2 (en) * 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
RU2440101C2 (ru) 2005-08-15 2012-01-20 Зольвай Фармасьютиклз Гмбх Фармацевтические композиции регулируемого высвобождения нестабильных в кислой среде лекарственных средств
US11266607B2 (en) * 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
JP5284092B2 (ja) 2005-08-15 2013-09-11 アボット ラボラトリーズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 腸溶コーティングに適したパンクレアチンマイクロペレットコア
US10072256B2 (en) * 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
MX2008014763A (es) 2006-05-22 2008-11-28 Solvay Pharm Gmbh Procedimiento para separar y determinar la carga virica en una muestra de pancreatina.
MX2009006597A (es) 2006-12-21 2009-07-02 Novozymes As Variantes de lipasa para uso farmaceutico.
TWI421090B (zh) 2007-02-20 2014-01-01 Aptalis Pharma Ltd 穩定之消化酵素組合物
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
US10087493B2 (en) * 2008-03-07 2018-10-02 Aptalis Pharma Canada Ulc Method for detecting infectious parvovirus in pharmaceutical preparations

Also Published As

Publication number Publication date
KR20080036622A (ko) 2008-04-28
CN101233229A (zh) 2008-07-30
KR101555058B1 (ko) 2015-09-22
IL189103A (en) 2012-03-29
EP2278002A1 (en) 2011-01-26
UA93384C2 (ru) 2011-02-10
HK1120288A1 (en) 2009-03-27
PL1913138T3 (pl) 2017-07-31
NO342419B1 (no) 2018-05-22
US20170073660A1 (en) 2017-03-16
RU2008107261A (ru) 2009-09-10
BRPI0614914A2 (pt) 2011-04-19
JP2009502876A (ja) 2009-01-29
US10704037B2 (en) 2020-07-07
CA2616943C (en) 2016-04-12
US20070148151A1 (en) 2007-06-28
NO20171131A1 (no) 2008-04-28
EP1913138A1 (en) 2008-04-23
IL189103A0 (en) 2008-08-07
PL2278002T3 (pl) 2017-12-29
HUE031042T2 (en) 2017-06-28
ES2597381T3 (es) 2017-01-18
EP2278002B1 (en) 2017-07-12
RU2413532C2 (ru) 2011-03-10
AU2006274835B2 (en) 2012-05-24
ES2635308T3 (es) 2017-10-03
US20200299669A1 (en) 2020-09-24
CN101233229B (zh) 2013-05-01
EP1913138B1 (en) 2016-08-24
JP5140586B2 (ja) 2013-02-06
NO340996B1 (no) 2017-07-31
AU2006274835A1 (en) 2007-02-08
MX2008000850A (es) 2008-03-18
HUE034739T2 (en) 2018-02-28
WO2007014896A1 (en) 2007-02-08
CA2616943A1 (en) 2007-02-08

Similar Documents

Publication Publication Date Title
NO20081087L (no) Fremgangsmater for fremstilling av sterilisert pankreatinpulver
Fu et al. Induction of Escherichia coli O157: H7 into a viable but non‐culturable state by high temperature and its resuscitation
PT2155221E (pt) Método para modificar materiais vegetais contendo polifenol e utilizações médicas de materiais vegetais modificados contendo polifenol
EP1831353A4 (en) NON-TUMORING MDCK CELL LINES FOR VIRUSING
NO20170687A1 (no) Fremgangsmåte for fermentering og dyrking, fermentert planteekstrakt, fermentert planteekstraktpulver og blanding inneholdende det fermenterte planteekstraktet
MY151119A (en) Duck embryonic derived stem cell lines for the production of viral vaccines
ATE541591T1 (de) Verfahren zur verringerung der viralen und mikrobiellen belastung von pankreatin
NO20071610L (no) Immunogen sammensetning
Kurepa et al. Friends in arms: Flavonoids and the auxin/cytokinin balance in terrestrialization
EA200870304A1 (ru) Псевдоинфекционный флавивирус и его применение
DE602006021503D1 (de) Mehlzusammensetzung mit erhöhtem Gesamtfasergehalt, Verfahren zu deren Herstellung und deren Verwendung
Donati et al. Stilbene biosynthesis and gene expression in response to methyl jasmonate and continuous light treatment in Vitis vinifera cv. Malvasia del Lazio and Vitis rupestris Du Lot cell cultures
WO2010022897A3 (de) Methoden zur verbesserung des pflanzenwachstums
Petrzik et al. Novel viruses that lyse plant and human strains of Kosakonia cowanii
Lal et al. Identification of a Novel Geminivirus in Fraxinus rhynchophylla in Korea
Ortiz et al. Genetically modified plants based on Bacillus genes and commercial Bacillus-based biopesticides for sustainable agriculture
Kumar et al. First report of Radish leaf curl virus infecting okra in India
Ben Gaied et al. Bacterial endophytes from Legumes native to arid environments are promising tools to improve Mesorhizobium–chickpea symbiosis under salinity
BRPI0823057A2 (pt) Planta da espécie cucumis melo, parte de planta, método para obter uma planta resistente a cvyv da espécie cucumis melo, planta resistente ao vírus do amarelecimento das nervuras do pepino (cvyv) da espécie cucumis melo, uso de pelo menos um marcador molecular, e resistência ao vírus do amarelecimento das nervuras do pedido (cvyv) conferindo locos de caracteres quantitativos (qtl), ou uma parte da mesma conferindo resistência a cvyv.
WO2010014248A3 (en) Antiviral activity of the protein scytovirin and methods of use
Samadelli et al. Theoretical aspects of physical-chemical parameters for the correct conservation of mummies on display in museums and preserved in storage rooms
BR0308736A (pt) Células de pulmão de rato cotton para cultura de vìrus
Mahajan et al. A wound inducible chalcone synthase gene from Dysoxylum gotadhora (DbCHS) regulates flavonoid biosynthesis
Shimoia et al. Co-Inoculation of Soybean Seeds with Azospirillum and/or Rhizophagus Mitigates the Deleterious Effects of Waterlogging in Plants under Enhanced CO2 Concentrations
EP4410970A3 (en) Efficient cell culture system for hepatitis c virus genotype 6a

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ABBOTT LABORATORIES GMBH, DE